Lucicriz Capsules — Crizotinib 250 mg (60 Caps) Lucius
LuciCriz 250 mg (Crizotinib) is an advanced targeted therapy antineoplastic agent (tyrosine kinase inhibitor). It works by specifically inhibiting the activity of mutated ALK (Anaplastic Lymphoma Kinase) and ROS1 proteins. These mutant proteins drive the uncontrolled growth of cancer cells; by blocking them, the medication halts tumor progression and induces tumor shrinkage.
Manufacturer: Lucius Pharmaceuticals. It is a high-quality, cost-effective generic equivalent to the brand-name drug Xalkori, designed for specific genetically profiled lung cancers.
Key Features:
- ✅ Precision Medicine: Targets only the cells carrying specific genetic mutations, minimizing damage to healthy tissues.
- ✅ Proven Efficacy: Significantly improves progression-free survival in patients with ALK-positive and ROS1-positive tumors.
- ✅ Convenience: Oral capsule formulation allows for easier home-based administration compared to intravenous chemotherapy.
Strictly prescribed by an oncologist following biomarker testing of the tumor. Indicated for the treatment of adult patients with:
- 🔹 Metastatic Non-Small Cell Lung Cancer (NSCLC):
- Whose tumors are ALK-positive.
- Whose tumors are ROS1-positive.
Sales Unit: Plastic bottle in a carton box containing 60 capsules. Strength: 250 mg per capsule.
⚠️ APPLICATION INSTRUCTIONS:
- Standard Dosage: The recommended dose is 250 mg (1 capsule) taken twice daily (morning and evening).
- Administration: Take at approximately the same times each day, with or without food. Swallow capsules whole; do not crush, open, or chew them.
- ✋ Crucial Dietary Warning: Strictly avoid consuming grapefruit or grapefruit juice during treatment, as it can dangerously increase the concentration of Crizotinib in the body.
- ⛔ Pregnancy and Breastfeeding: Can cause fetal harm. Highly effective contraception must be used by both men and women during treatment and for at least 90 days after the last dose.
- Severe hepatic impairment.
- Congenital long QT syndrome.
- Children and adolescents under 18 years of age.
A hallmark side effect of Crizotinib is visual impairment (very common, usually occurring early in treatment). Potential adverse reactions include:
- 👁️ Vision Disorders: Flashes of light, blurred vision, double vision, or floaters (usually transient or manageable with dose adjustment).
- 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, constipation.
- 💧 Edema: Peripheral edema (swelling of the hands, feet, or face).
- 🔶 Liver: Hepatotoxicity/elevated liver enzymes (requires regular blood monitoring).
- ❤️ Cardiac: Decreased heart rate (bradycardia).
Similar products
What Customers Say
No reviews yet
Your review can be the first!